{"name":"Dragonboat Biopharmaceutical Company Limited","slug":"dragonboat-biopharmaceutical-company-limited","ticker":"","exchange":"","domain":"dragonboatbiopharmaceuticalcompany.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BC006","genericName":"BC006","slug":"bc006","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]}],"pipeline":[{"name":"BC006","genericName":"BC006","slug":"bc006","phase":"phase_2","mechanism":"BC006 is a monoclonal antibody targeting the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxQZmU1d295d19RSDZ3ZzNiSGV2VWpnQzc3bW9LM015ektaTlhKZFR5NXNiLTRUOGc5M055QkhGX2xoMzVZbkVsRU1jN3I3Tm1zOEVlZlBsLUgyTkJuNDJLRXFISWtodDBBWllNSTZ3UU13OEtYRmlIY0c0RnJCZDg2ZzJqYnVoUXRWSWstamx3cVNvMXF6d1NmRGR6QUYzRnFfVDdDQjYzTTZmT1FwMG95UWZZNGVVUjR2bENlSEt5RnVpQ2M3Znc5c3BYTlRLVU1vMWdMRUJVTXpqa2wyZHRlZWc1d0hjcmdpOHdjZUsySlNodWI2Zjc0bW5hQmVsdnVxX2tiNWpQVHJoM0hGM19VVE1tbkdQZjlJM0FvYTBqZUE0R2w3YUF5UUhWODBsQmF2Q3pzdmtR?oc=5","date":"2022-06-26","type":"trial","source":"prnewswire.com","summary":"Congratulations to Dragon Boat Biopharmaceutical from Sanyou Biopharmaceuticals on the NMPA acceptance of the CLDN 18.2/CD47 bsAb clinical trial application - prnewswire.com","headline":"Congratulations to Dragon Boat Biopharmaceutical from Sanyou Biopharmaceuticals on the NMPA acceptance of the CLDN 18.2/","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxPVXlyX29TQU1EWlNzS21JaGlqSTlrNE5BeDZIOHRERHR3M1gzbnFEOHo3RWg1N0QzcEotYVUwMnBzWjM4YnVnYThjVldGemVscVBDcVl4RG9EZVg5WkY4eGZHNGtYVjIyNUNMbjVlb1NQTDRWT2Nfa3ZlSE9LbDJKX0ZuNUNKVjlOZ2h5ZVBRMlducDBnUC13SzgxNEdIbWpxa2M3Mzc0Ml9mV1p3VXg1UWMtUG5JZmZVTGJPbGwtMFRHXzdXNHJMTHhoblF6dFJ1YXMwak9rR2hfM3luME9Dd2lPWlNxeHVPX19CaUJVOHExaWNoMVFyeDFvV2pBNDA4ZnhmSWR0R2NRa0Fp?oc=5","date":"2022-04-20","type":"regulatory","source":"prnewswire.com","summary":"Sanyou Bio congratulates Dragon Boat Pharmaceutical on the approval of clinical trials of anti-CLDN18.2 antibody drug BC008 - prnewswire.com","headline":"Sanyou Bio congratulates Dragon Boat Pharmaceutical on the approval of clinical trials of anti-CLDN18.2 antibody drug BC","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNZk1lb0RORXB3N0FkTUdHX1JPODZKVEFZVk1jS1psbnF2RDJIZXR4ZG0zbmJWaXdTWVNxaDl5Q21JbU9MUXU5dmlUeTB1Rlkzd1NIMHFQYjgtMU1PUFpTLXBLUTBwb1NmLVJrc1BTd1ZZRjVNNUhYQzMycUVfc3JUdkNpZXhPSzA3MUNYUUVBc0swZnZ4TXJJdFpkemJPcWxSaG13dFM0VzdBdmNFRWlheHJhemhtUmM?oc=5","date":"2021-03-23","type":"pipeline","source":"BioWorld News","summary":"Dragon Boat moves anti-CSF-1R antibody candidate to the clinic - BioWorld News","headline":"Dragon Boat moves anti-CSF-1R antibody candidate to the clinic","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}